2021 WCLC Highlights

CME

Independent Conference Coverage of the IASLC 2021 World Conference on Lung Cancer

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 18, 2021

Expiration: November 17, 2022

Anne Chiang
Anne Chiang, MD, PhD
Thomas Stinchcombe
Thomas Stinchcombe, MD

Activity

Progress
1
Course Completed

References

  1. Lurbinectedin prescribing information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2021.
  2. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
  3. Paz-Ares L, Ciuleanu T, Navarro A, et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS trial. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract PL02.03.
  4. Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618-627.
  5. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883-895.
  6. Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369-2379.
  7. Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39:1349-1359.
  8. Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32:631-641.
  9. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab vs best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8500.
  10. Altorki N, Felip E, Zhou C, et al. IMpower010: Characterization of stage IB-IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract PL02.05.
  11. Atezolizumab prescribing information. South San Francisco, CA: Genentech Inc.; 2021.
  12. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8511.
  13. Provencio M, Nadal E, Insa A, et al. Long term survival in operable stage IIIA NSCLC patients treated with neoadjuvant nivolumab plus chemotherapy - Nadim study. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA20.01.
  14. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413-1422.
  15. Bondarenko I, Sezer A, Kilickap S, et al. Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-Lung 1. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract FP04.03.
  16. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.
  17. Cemiplimab-rwlc prescribing information. Tarrytown, NY: Regeneron Pharmaceuticals Inc.; 2021.
  18. Johnson M, Cho BC, Luft A, et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract PL02.01.
  19. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198-211.
  20. ClinicalTrials.gov. EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis. clinicaltrials.gov/ct2/show/NCT03793179. Accessed November 7, 2021.
  21. Carbone DP, Ciuleanu T-E, Cobo M, et al. First-line nivolumab + ipilimumab + chemotherapy in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA09.01.
  22. Waqar SN, Samson PP, Robinson CG, et al. Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018;19:e373-e379.
  23. Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3:827-831.
  24. Sun L, Davis CW, Hwang WT, et al. Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy. Clin Lung Cancer. 2021;22:58-66.e3.
  25. Nadal E, Rodríguez-Abreu D, Massutí B, et al. ATEZO-BRAIN: Non-randomized phase II clinical trial of atezolizumab combined with carboplatin plus pemetrexed in chemotherapy-naive patients with advanced non-squamous NSCLC with untreated brain metastases. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA09.02.
  26. Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:655-663.
  27. Gadgeel SM, Dziubek K, Nagasaka M, et al. Pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-positive non-small cell lung cancer (NSCLC). Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA09.03.
  28. ClinicalTrials.gov. Study of pemetrexed + platinum chemotherapy with or without pembrolizumab (MK-3475) in adults with tyrosine kinase inhibitor- (TKI)-resistant epidermal growth factor receptor- (EGFR)-mutated metastatic non-squamous non-small cell lung cancer (NSCLC) (MK-3475-789/KEYNOTE-789). clinicaltrials.gov/ct2/show/NCT03515837. Accessed November 7, 2021.
  29. Amivantamab-vmjw prescribing information. Horsham, PA: Janssen Biotech, Inc.; 2021.
  30. Mobocertinib prescribing information. Tokyo, Japan: Takeda Pharmaceuticals, Inc.; 2021.
  31. Jänne PA, Wang M, Mitchell P, et al. Phase 1 studies of DZD9008, an oral selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR exon20 insertion mutations. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA15.02.
  32. ClinicalTrials.gov. An expanded access protocol for mobocertinib in refractory non-small cell lung cancer (NSCLC) participants with epidermal growth factor receptor (EGFR) exon20 insertion mutations. clinicaltrials.gov/ct2/show/NCT04535557. Accessed November 7, 2021.
  33. Zhou C, et al. Mobocertinib in NSCLC with EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations. Presented at: 2020 IASLC World Conference on Lung Cancer; January 28-31, 2021. Abstract OA04.03.
  34. Spira A, Ramalingam S, Neal J, et al. Mobocertinib in EGFR exon 20 insertion–positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA15.01.
  35. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391-3402.
  36. Spira A, Krebs M, Cho BC, et al. Amivantamab in non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation: initial results from CHRYSALIS. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA15.03.
  37. Amatu A, Sartore-Bianchi A, Bencardino K, et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30(suppl_8):viii5-viii15.
  38. Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol. 2018;2018:PO.18.00037.
  39. Larotrectinib prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; 2018
  40. Entrectinib prescribing information. Stamford, CT: Loxo Oncology; 2018.
  41. Drilon A, Lin J, Lassen U, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract P53.02.
  42. Thompson J, Aggarwal C, Wong J, et al. Plasma NGS at time of diagnostic tissue biopsy – impact on time to treatment: results from a pilot prospective study. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract OA16.01.
  43. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.
  44. Okajima D, Yamaguchi J, Kitamura M, et al. DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models. Presented at: AACR-NCI-EORTC 2019. Abstract C026.
  45. Garon E, Johnson M, Lisberg A, et al. TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract MA03.02.
  46. Adusumilli P. CAR T-cell therapy for thoracic cancers. Presented at: 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021. Abstract PL05.01.
  47. Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748-2763.